-
May 21, 2024 | 
biorxiv.org | Joseph Roy |Ross MacLeod |Ross Macleod |Liverpool John Moores
AbstractInfrared thermography is a promising tool for assessing proxy for stress response in animals. With the advancement of longer recording capabilities, this technique allows the monitoring of the dynamic nature of the temperature variation which is highly correlated to the stress faced by the animal.
-
Apr 10, 2024 | 
mdpi.com | Ross MacLeod |Ross Macleod |G. Matt Davies |Tjalle Boorsma |Jo Peacock
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Mar 29, 2024 | -bill-reflections-on-policy-and-politics/&sz=64)
gwct.org.uk | Ross MacLeod |Ross Macleod
By Ross Macleod, Head of Policy (Scotland)So, the Wildlife Management and Muirburn (Scotland) Bill has passed through Scottish Parliament, marking nearly seven years of scrutiny, originating with the implementation of the Werritty Grouse Management Review in 2017. The starting point, of course, focused on raptor persecution and extended to consider other elements of moorland management.
-
Mar 28, 2024 | 
gwct.org.uk | Ross MacLeod |Ross Macleod
By Ross Macleod, Head of Policy (Scotland)If we hoped for some respite from the weight of policy consultations, bills and legislation that confronted us in 2023, the barrage has continued unabated so far this year.
-
Mar 6, 2024 | 
globenewswire.com | Ross MacLeod |Ross Macleod
Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.
-
Nov 13, 2023 | 
gwct.org.uk | Ross MacLeod |Ross Macleod
By Ross Macleod, Head of GWCT Policy (Scotland)It is very difficult to come to terms with the Environment Minister Gillian Martin MSP’s decision to ban all types of snares in Scotland given the resulting prospects for rural management and biodiversity. Soul-destroying even. Not because we don’t appreciate the arguments around animal welfare.
-
Oct 12, 2023 | 
gwct.org.uk | Ross MacLeod |Ross Macleod |GWCT Head
By Ross MacLeod, GWCT Head of Policy, ScotlandThe pressing need to respond to global climate change and biodiversity loss is undoubtedly driving a large part of our Scottish policy work this year, with government consultations, draft legislation, parliamentary evidence sessions and more coming our way.
-
Sep 22, 2023 | 
nzherald.co.nz | Ross MacLeod |Ross Macleod
Perfectly timed for Mental Health Awareness Week, The Manic Monologues is a collection of real stories of mental illness delivered by a selection of actors. Carving in Ice has a solid track record of interview style theatre and once again the company delivers a poignant, and respectful exploration of the theme. There’s a broad range of stories, varying in detail, length and the nature of the mental illness.
-
Jul 18, 2023 | 
globenewswire.com | Ross MacLeod |Ross Macleod
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it has successfully completed a discovery campaign against CXCR6, an undrugged small protein GPCR with the potential to provide a new and innovative form of immunotherapy treatment for solid tumor cancers.
-
Feb 16, 2023 | 
globenewswire.com | Ross MacLeod |Ross Macleod
Ottawa, Canada, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be attending the 2nd GPCR-Targeted Drug Discovery Summit in Boston from February 21st-23rd. Dr. Oliver Hartley, Orion’s Vice President of Drug Discovery, will be presenting on February 23rd at 11:15 AM EST.
